Investigators, including our group, have demonstrated that an increase in PRMT5 expression is associated with a worse GBM prognosis; furthermore, studies have reported a direct correlation between PRMT5 expression and grade of glioma malignancy (Table 1) [76,77]. This evidence concerns the gene PRMT5 and central nervous system cancer.